Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allen DB, Rundle AC, Graves DA, Blethen S (1997). Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 131:S32–36.
Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R (1996) Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 81:1704–1710.
Critical Evaluation of the Safety of Recombinant Human Growth Hormone Administration: Statement from the Growth Hormone Research Society.(2001) J Clin Endocrinol Metab 86:1868–1870.
Hara T, Komiyama A, Ono H, Akabane T (1989) Acute lymphoblastic leukemia in a patient with pituitary dwarfism under treatment with growth hormone. Acta Paediatr Jpn 31:73–77.
Hintz RL (1995) The prismatic case of creutzfeldt-jakob disease associated with pituitary growth hormone treatment. J Clin Endocrinol Metab 80:2298–2301.
Hintz RL (1996) Eternal vigilance—mortality in children with growth hormone deficiency. J Clin Endocrinol Metab 81:1691–1692, 1996.
Hintz RL, Rosenfeld RG, Wilson DM, Bennett A, Fenno J, McClellan B, Swift R (1982) Biosynthetic methionyl-human growth hormone is biologically active in adult man. Lancet I:1276–1279.
Kaplan SL, Underwood LE, August GP, Bell JJ, Blethen SL, Blizzard RM, Brown DR, Foley TP, Hintz RL, Hopwood NJ, Johansen A, Plotnik LP, Underwood NJ, Kirkland RT, Rosenfeld RG, Vanwyk JJ (1986) Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet 1:697–700.
Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV (1995) Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 126:996–999.
Maneatis T, Baptista J, Connelly K, Blethen S (2000) Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab 13Suppl 2:1035–1044.
Mills JL, Schonberger LB, Wysowski DK, Brown P, Durako SJ, Cox C, Kong F, Fradkin JE (2004) Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 144:430–436.
Nishi Y, Tanaka T, Takano K, Fujieda K, Igarashi Y, Hanew K, Hirano T, Yokoya S, Tachibana K, Saito T, Watanabe S (1999) Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. J Clin Endocrinol Metab 84:1961–1965.
Sherman BM (1987) A National Cooperative Growth Study of Protropin. (Acta Paediatr Scand Suppl. 337:106–108.
Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robison LL (2002) Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 87:3136–3141.
Swerdlow AJ, Higgins CD, Adlard P, Preece MA (2002) Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet 360:273–277.
Taback SP, Dean HJ (1996) Mortality in Canadian children with growth hormone (GH) deficiency receiving GH therapy 1967–1992. The Canadian Growth Hormone Advisory Committee. J Clin Endocrinol Metab 81:1693–1696.
Taha DR, Bastian W, Castells S (2001) Growth hormone replacement therapy in children with leukemia in remission. Clin Pediatr (Phila) 40:441–445.
Wyatt D (2004) Lessons from the National Cooperative Growth Study. EurJ Endocrinol 151: S55–S59.
Appendix 1: Chronological List of NCGS Publications 1987–2004
Sherman BM. A National Cooperative Growth Study of Protropin. (1987) Acta Paediatr Scand Suppl 337:106–108.
August GP, Lippe BM, Blethen SL, Rosenfeld RG, Seelig SA, Johanson AJ, Compton PG, Frane JW, McClellan BH, Sherman BM. (1990) Growth hormone treatment in the United States: demographic and diagnostic features of 2331 children. J Pediatr 116:899–903.
Rosenfeld RG. Growth hormone therapy in Turner’s syndrome: an update on final height. Genentech National Cooperative Study Group. (1992) Acta Paediatr Suppl Sep; 383:3–6.
Blethen SL, Compton P, Lippe BM, Rosenfeld RG, August GP, Johanson A. (1993) Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. J Clin Endocrinol Metab 76:574–579.
Stabler B, Clopper RR, Siegel PT, Stoppani C, Compton PG, Underwood LE. (1994) Academic achievement and psychological adjustment in short children. The National Cooperative Growth Study. J Dev Behav Pediatr 15:1–6.
Carlsson LM, Attie KM, Compton PG, Vitangcol RV, Merimee TJ. (1994) Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. National Cooperative Growth Study. J Clin Endocrinol Metab 78:1325–1330.
Kaplowitz PB. (1995) Effect of growth hormone therapy on final versus predicted height in short twelve-to sixteen-year-old boys without growth hormone deficiency. J Pediatr 126:478–480.
Vassilopoulou-Sellin, Klein MJ, Moore BD 3rd, Reid HL, Ater J, Zietz HA. Efficacy of growth hormone replacement therapy in children with organic growth hormone deficiency after cranial irradiation.(1995) Horm Res 43:188–193.
Tuffli GA, Johanson A, Rundle AC, Allen DB. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. (1995) J Clin Endocrinol Metab 80:1416–1422.
Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. (1995) J Pediatr 126:996–999.
Attie KM, Carlsson LM, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. The National Cooperative Growth Study. (1995) J Pediatr 127:244–250.
Hintz RL, Attie KM, Compton PG, Rosenfeld RG. (1995) Multifactorial studies of GH treatment of Turner syndrome: The Genentech National Cooperative Growth Study. In: Turner Syndrome in a Life-Span Perspective. Ed: K. Albertsson-Wikland and B. Lippe. Elsevier, Amsterdam pp 167–173.
Growth Hormone: Science, Research, and the NCGS. (1986) NCGS Advisory Group. Gardiner-Caldwell Synermed. Califon, New Jersey.
Blethen SL, Rundle AC. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. (1996) Horm Res 46:113–116.
Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. (1996) Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 81:1704–1710.
Graves DA. Utility of the National Cooperative Growth Study database for safety reporting. (1996) J Pediatr. 128 (5 Pt 2):S1–3.
National Cooperative Growth Study: Ten Years of Guidance in Growth. Proceedings of a meeting. New York, October 12-15, 1995. (1996) J Pediatr 128 (5 Pt 2):S1–62.
Key LL Jr, Gross AJ. Response to growth hormone in children with chondrodysplasia.(1996) J Pediatr. 128 (5 Pt 2):S14–17.
Romano AA, Blethen SL, Dana K, Noto RA. Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience. (1996) J Pediatr 128 (5 Pt 2):S18–21.
Rogol AD, Breen TJ, Attie KM. National Cooperative Growth Study substudy. II: Do growth hormone levels from serial sampling add important diagnostic information? (1996) J Pediatr 128 (5 Pt 2):S42–46.
Chernausek SD, Breen TJ, Frank GR. Linear growth in response to growth hormone treatment in children with short stature associated with intrauterine growth retardation: the National Cooperative Growth Study experience. (1996) J Pediatr. 128 (5 Pt 2):S22–27.
Rotenstein D, Breen TJ. Growth hormone treatment of children with myelomeningocele. (1996) J Pediatr 128 (5 Pt 2):S28–31.
Blethen SL, Breen TJ, Attie KM. Overview of the National Cooperative Growth Study substudy of serial growth hormone measurements. (1996) J Pediatr 128(5 Pt 2):S38–41.
Moshang T Jr, Rundle AC, Graves DA, Nickas J, Johanson A, Meadows A. Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. (1996) J Pediatr. 128 (5 Pt 2):S4–7.
Rogol AD, Breen TJ, Attie KM. National Cooperative Growth Study substudy. II: Do growth hormone levels from serial sampling add important diagnostic information? (1996) J Pediatr 128(5 Pt 2):S42–46.
Allen DB. Safety of human growth hormone therapy: current topics. (1996) J Pediatr 128 (5 Pt 2):S8–13.
Allen DB, Rundle AC, Graves DA, Blethen SL. Risk of leukemia in children treated with human growth hormone: review and reanalysis. (1997) J Pediatr 131 (1 Pt 2):S32–36.
Mentser M, Breen TJ, Sullivan EK, Fine RN. Growth-hormone treatment of renal transplant recipients: the National Cooperative Growth Study experience—a report of the National Cooperative Growth Study and the North American Pediatric Renal Transplant Cooperative Study. (1997) J Pediatr 131(1 Pt 2):S20–24.
Allen DB, Rundle AC, Graves DA, Blethen SL. Risk of leukemia in children treated with human growth hormone: review and reanalysis. (1997) J Pediatr 131 (1 Pt 2):S32–36.
Attie KM, Julius JR, Stoppani C, Rundle AC. National Cooperative Growth Study substudy VI: the clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements.(1997) J Pediatr 131 (1 Pt 2): S56–60.
Hardin DS, Sy JP. Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience.(1997) J Pediatr 131 (1 Pt 2):S65–69.
Stephure DK, Blethen SL, McClellan BH. National Cooperative Growth Study substudy VIII: a new look at the natural history of short stature. (1997) J Pediatr 131 (1 Pt 2):S81–82.
Cronin MJ. Pioneering recombinant growth hormone manufacturing: pounds produced per mile of height. (1997) J Pediatr 131 (1 Pt 2):S5–7.
Goddard AD, Dowd P, Chernausek S, Geffner M, Gertner J, Hintz R, Hopwood N, Kaplan S, Plotnick L, Rogol A, Rosenfield R, Saenger P, Mauras N, Hershkopf R, Angulo M, Attie K. Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature. (1997) J Pediatr 131 (1 Pt 2):S51–55.
Proceedings of the National Cooperative Growth Study 10th Annual Investigators Meeting. San Francisco, California, October 17-20, 1996. Dedicated to the memory of Dr. Michael J. Cronin. (1997) J Pediatr 131 (1 Pt 2):S1–82.
Silverman BL, Friedlander JR. Is growth hormone good for the heart? (1997) J Pediatr 131 (1 Pt 2):S70–74.
Siegel PT, Clopper R, Stabler B. The psychological consequences of Turner syndrome and review of the National Cooperative Growth Study psychological substudy. (1998) Pediatrics 102 (2 Pt 3):488–491.
Stabler B, Siegel PT, Clopper RR, Stoppani CE, Compton PG, Underwood LE. Behavior change after growth hormone treatment of children with short stature. (1998) J Pediatr 133:366–373.
Root AW, Kemp SF, Rundle AC, Dana K, Attie KM. (1998) Effect of long-term recombinant growth hormone therapy in children—the National Cooperative Growth Study, USA, 1985–1994. J Pediatr Endocrinol Metab 11:403–412.
Plotnick L, Attie KM, Blethen SL, Sy JP. Growth hormone treatment of girls with Turner syndrome: the National Cooperative Growth Study experience. (1998) Pediatrics 102 (2 Pt 3):479–481.
Siegel PT, Clopper R, Stabler B. The psychological consequences of Turner syndrome and review of the National Cooperative Growth Study psychological substudy. (1998) Pediatrics 102 (2 Pt 3):488–491.
Rao JK, Julius JR, Breen TJ, Blethen SL. Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy. (1998) Pediatrics 102 (2 Pt 3):497–500.
August GP, Julius JR, Blethen SL. Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the National Cooperative Growth Study experience. (1998) Pediatrics 102 (2 Pt 3):512–516.
MacGillivray MH, Blethen SL, Buchlis JG, Clopper RR, Sandberg DE, Conboy TA. Current dosing of growth hormone in children with growth hormone deficiency: how physiologic? (1998) Pediatrics 102 (2 Pt 3):527–530.
Bell JJ, Dana K. Lack of correlation between growth hormone provocative test results and subsequent growth rates during growth hormone therapy. (1998) Pediatrics 102 (2 Pt 3):518–520.
Diamond FB, Jorgensen EV, Root AW, Shulman DI, Sy JP, Blethen SL, Bercu BB. The role of serial sampling in the diagnosis of growth hormone deficiency. (1998) Pediatrics 102 (2 Pt 3):521–524.
Hintz RL. The role of auxologic and growth factor measurements in the diagnosis of growth hormone deficiency. (1998) Pediatrics 102 (2 Pt 3):524–526.
Allen DB, Julius JR, Breen TJ, Attie KM. (1998) Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 83:2824–2829.
National Cooperative Growth Study: Guidance in Growth. Proceedings of the National Cooperative 11th annual investigators meeting. Washington, DC, USA. September 25-28, 1997. (1998) Pediatrics 102 (2 Pt 3):iv, 479–530.
Kaplowitz PB, Rundle AC, Blethen SL. Weight relative to height before and during growth hormone therapy in prepubertal children. (1998) Horm Metab Res 30:565–569.
Root AW, Kemp SF, Rundle AC, Dana K, Attie KM. Effect of long-term recombinant growth hormone therapy in children — the National Cooperative Growth Study, USA, 1985–1994. (1998) J Pediatr Endocrinol Metab 11:403–412.
National Cooperative Growth Study: Guidance in Growth. Proceedings of the National Cooperative Growth Study 12th Annual Investigators Meeting. New Orleans, Louisiana, USA. October 8-11, 1998. (1999) Pediatrics 104 (4 Pt 2):999–1049.
Sandra L. Blethen. Leukemia in Children Treated with Growth Hormone. (1998) Trends in Endocrin Metabol 9:367–370.
Frindik JP, Kemp SF, Sy JP. Effects of recombinant human growth hormone on height and skeletal maturation in growth hormone-deficient children with and without severe pretreatment bone age delay. (1999) Horm Res 51:15–19.
Petryk A, Richton S, Sy JP, Blethen SL. The effect of growth hormone treatment on stature in Aarskog syndrome.(1999) J Pediatr Endocrinol Metab 12:161–165.
Castells S, Chakurkar A, Qazi Q, Bastian W. Robinow syndrome with growth hormone deficiency: treatment with growth hormone. (1999) J Pediatr Endocrinol Metab 12:565–571.
Frindik JP, Baptista J. (1999) Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Pediatrics 104 (4 Pt 2):1000–1004.
Kohn B, Julius JR, Blethen SL. (1999) Combined use of growth hormone and gonadotropin-releasing hormone analogues: the national cooperative growth study experience. Pediatrics 104 (4 Pt 2):1014–1018.
Bright GM, Julius JR, Lima J, Blethen SL. Growth hormone stimulation test results as predictors of recombinant human growth hormone treatment outcomes: preliminary analysis of the national cooperative growth study database. (1999) Pediatrics 104 (4 Pt 2):1028–1031.
Kemp SF, Sy JP. Analysis of bone age data from national cooperative growth study substudy VII. (1999) Pediatrics 104 (4 Pt 2):1031–1036.
Kaufman FR, Sy JP. Regular monitoring of bone age is useful in children treated with growth hormone. (1999) Pediatrics 104 (4 Pt 2):1039–1042.
Wyatt D. Melanocytic nevi in children treated with growth hormone. (1999) Pediatrics 104 (4 Pt 2):1045–1050.
Blackett PR, Rundle AC, Frane J, Blethen SL. Body mass index (BMI) in Turner Syndrome before and during growth hormone (GH) therapy. (2000) Int J Obes Relat Metab Disord 24:232–235.
August GP, Lightner ES, Root AW. Survey of clinical practice: growth hormone use during illness. (2000) J Pediatr Endocrinol Metab 13Suppl 2:1031–1033.
Maneatis T, Baptista J, Connelly K, Blethen S. Growth hormone safety update from the National Cooperative Growth Study. (2000) J Pediatr Endocrinol Metab 13Suppl 2:1035–1044.
Wright NM. Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis.(2000) J Pediatr Endocrinol Metab 13Suppl 2:999–1002.
Reiter EO, Blethen SL, Baptista J, Price L. Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner’s syndrome. (2001) J Clin Endocrinol Metab 86:1936–1941.
Taha DR, Bastian W, Castells S. Growth hormone replacement therapy in children with leukemia in remission. (2001) Clin Pediatr (Phila) 40:441–445.
Kemp SF, Alter CA, Dana K, Baptista J, Blethen SL. Use of magnetic resonance imaging in short stature: data from National Cooperative Growth Study (NCGS) Substudy 8. (2002) J Pediatr Endocrinol Metab 15Suppl 2:675–679.
Meacham LR, Sullivan K. Characteristics of growth hormone therapy for pediatric patients with brain tumors in the National Cooperative Growth Study (NCGS) and from a survey of pediatric endocrinologists. (2002) J Pediatr Endocrinol Metab 15Suppl 2:689–696.
Parker KL, Hunold JJ, Blethen SL. Septo-optic dysplasia/optic nerve hypoplasia: data from the National Cooperative Growth Study (NCGS). (2002) J Pediatr Endocrinol Metab 15Suppl 2:697–700.
Reeves GD, Doyle DA. Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship? (2002) J Pediatr Endocrinol Metab 15Suppl 2:723–730.
Frindik JP, Kemp SF, Hunold JJ. Near adult heights after growth hormone treatment in patients with idiopathic short stature or idiopathic growth hormone deficiency. (2003) J Pediatr Endocrinol Metab 16Suppl 3:607–612.
Levy RA, Connelly K. Diagnostic growth hormone deficiency testing practices among patients in the NCGS/NCSS databases. (2003) J Pediatr Endocrinol Metab 16Suppl 3:619–624.
Parker KL, Wyatt DT, Blethen SL, Baptista J, Price L. Screening girls with Turner syndrome: the National Cooperative Growth Study experience. (2003) J Pediatr 143:133–135.
Proceedings of the 16th Annual National Cooperative Growth Study (NCGS) and the 3rd Annual National Cooperative Somatropin Surveillance (NCSS) Investigator Meeting. Chicago, Illinois, USA. October 17–20, 2002. (2003) J Pediatr Endocrinol Metab 16Suppl 3:585–690.
Bell JJ, August GP, Blethen SL, Baptista J. Neonatal hypoglycemia in a growth hormone registry: incidence and pathogenesis. (2004) J Pediatr Endocrinol Metab 17:629–635.
Wyatt D. Lessons from the national cooperative growth study. (2004) Eur J Endocrinol 151Suppl 1:S55–59.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hintz, R.L. (2005). The Importance of the National Cooperative Growth Study (NCGS). In: Carel, JC., Kelly, P.A., Christen, Y. (eds) Deciphering Growth. Research and Perspectives in Endocrine Interactions. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28902-X_11
Download citation
DOI: https://doi.org/10.1007/3-540-28902-X_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-26192-6
Online ISBN: 978-3-540-28902-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)